XML 54 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814
Commitments and Contingencies
12 Months Ended
Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 5 – Commitments and Contingencies

Commitments and contingencies are described below and summarized by the following table as of June 30, 2014:

 

     Total      2016      2017      2018      2019      2020      Thereafter  

Management fee

   $ 1,800,000       $ 360,000       $ 360,000       $ 360,000       $ 360,000       $ 360,000       $ —     

ProstaScint Inventory Transfer

     500,000         500,000         —           —           —           —           —     

Sponsored research agreement with related party

     350,000         70,000         70,000         70,000         70,000         70,000         —     

Clinical research and trial obligations

     329,000         329,000         —           —           —           —           —     

Manufacturing

     133,000         133,000         —           —           —           —           —     

Office Lease

     110,000         35,000         36,000         36,000         3,000         —           —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 
   $ 3,222,000       $ 1,427,000       $ 466,000       $ 466,000       $ 433,000       $ 430,000       $ —     
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Management Fee

In July 2015, Aytu entered into agreements with Ampio whereby Aytu agreed to pay Ampio $30,000 per month for shared overhead which includes costs related to the shared facility, corporate staff, and other miscellaneous overhead expenses. These agreements will be in effect until they are terminated in writing by both parties.

ProstaScint Inventory Transfer Fee

Aytu is obligated to pay $500,000 for the ProstaScint-related product inventory upon the inventory transfer in July 2015.

Sponsored Research Agreement with Related Party

Aytu entered into a Sponsored Research Agreement with Trauma Research LLC (“TRLLC”), a related party, in June 2013. Under the terms of the Sponsored Research Agreement, TRLLC agreed to work collaboratively in advancing the RedoxSYS System diagnostic platform through research and development efforts. The Sponsored Research Agreement may be terminated without cause by either party on 30 days’ notice.

Clinical Research and Trial Obligations

In connection with the Zertane clinical trials and RedoxSYS research studies, the remaining commitment is $329,000.

 

Aytu Manufacturing and Commercial Development

Aytu entered into agreements with manufacturing companies to build its RedoxSYS system. The current remaining commitment is $133,000.

Office Lease

In June 2015, Aytu entered into a 37 month operating lease. This lease has initial base rent of $2,900 a month, with total base rent over the term of the lease of approximately $112,000. The Company recognizes rental expense of the facility on a straight-line basis over the term of the lease. Differences between the straight-line net expenses on rent payments are classified as liabilities between current deferred rent and long-term deferred rent. Rent expense for the respective periods is as follows:

 

     Years Ended June 30,  
     2015      2014  

Rent expense

   $ 51,000       $ 11,000